4.7 Review

Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment

Journal

ADVANCED DRUG DELIVERY REVIEWS
Volume 188, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.addr.2022.114445

Keywords

Drug combination; Phytochemicals; Drug resistance; Nanosystem; Co -delivery

Funding

  1. National Natural Science Foundation of China [81874380, 82022075, 81973662]
  2. Zhejiang Provincial Nat- ural Science Foundation of China for Distinguished Young Scholars [LR18H160001]
  3. Sichuan Provincial Natural Science Foundation for Distinguished Young Scholars [2019JDJQ0049]
  4. Zhejiang Provincial Natural Science Foundation of China [LQ21H160038]
  5. Zhejiang Province Science and Technology Project of TCM [2019ZZ016]

Ask authors/readers for more resources

This article discusses the synergistic anticancer effects and related mechanisms of combined therapy using chemotherapeutic drugs and natural compounds, aiming to enhance the efficacy of cancer treatment and reduce adverse consequences. In addition, the design and application of nano drug delivery systems for co-delivery of drugs can also improve anticancer efficacy.
The therapeutic limitations such as insufficient efficacy, drug resistance, metastasis, and undesirable side effects are frequently caused by the long duration monotherapy based on chemotherapeutic drugs. mul-tiple combinational anticancer strategies such as nucleic acids combined with chemotherapeutic agents, chemotherapeutic combinations, chemotherapy and tumor immunotherapy combinations have been embraced, holding great promise to counter these limitations, while still taking including some potential risks.Nowadays, an increasing number of research has manifested the anticancer effects of phytochemicals mediated by modulating cancer cellular events directly as well as the tumor microenvironment. Specifically, these natural compounds exhibited suppression of cancer cell proliferation, apoptosis, migration and invasion of cancer cells, P-glycoprotein inhibition, decreasing vascularization and activa-tion of tumor immunosuppression. Due to the low toxicity and multiple modulation pathways of these phytochemicals, the combination of chemotherapeutic agents with natural compounds acts as a novel approach to cancer therapy to increase the efficiency of cancer treatments as well as reduce the adverse consequences. In order to achieve the maximized combination advantages of small-molecule chemother-apeutic drugs and natural compounds, a variety of functional nano-scaled drug delivery systems, such as liposomes, host-guest supramolecules, supramolecules, dendrimers, micelles and inorganic systems have been developed for dual/multiple drug co-delivery. These co-delivery nanomedicines can improve pharmacokinetic behavior, tumor accumulation capacity, and achieve tumor site-targeting delivery. In that way, the improved antitumor effects through multiple-target therapy and reduced side effects by decreasing dose can be implemented. Here, we present the synergistic anticancer outcomes and the related mechanisms of the combination of phytochemicals with small-molecule anticancer drugs. We also focus on illustrating the design concept, and action mechanisms of nanosystems with co-delivery of drugs to synergistically improve anticancer efficacy. In addition, the challenges and prospects of how these insights can be translated into clinical benefits are discussed.(c) 2022 Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available